|
US5019368A
(en)
|
1989-02-23 |
1991-05-28 |
Cancer Biologics, Inc. |
Detection of necrotic malignant tissue and associated therapy
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TW225528B
(enExample)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
|
US5641863A
(en)
|
1993-09-30 |
1997-06-24 |
University Of Pennsylvania |
Chimeric IgG Fc receptors
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
PL188959B1
(pl)
|
1995-07-06 |
2005-05-31 |
Novartis Ag |
Pirolopirymidyny i sposoby ich wytwarzania
|
|
GB9518220D0
(en)
|
1995-09-06 |
1995-11-08 |
Medical Res Council |
Checkpoint gene
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
CN100503580C
(zh)
|
1996-04-12 |
2009-06-24 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂
|
|
BR9709959A
(pt)
|
1996-06-24 |
2000-05-09 |
Pfizer |
Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
|
|
WO1998010767A2
(en)
|
1996-09-13 |
1998-03-19 |
Sugen, Inc. |
Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
JPH10234372A
(ja)
|
1997-02-27 |
1998-09-08 |
Boehringer Mannheim Corp |
キメラ受容体を有する細胞とその作成方法、並びに その利用
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
US20020004041A1
(en)
|
1999-02-19 |
2002-01-10 |
Albert Matthew L. |
Methods for abrogating a cellular immune response
|
|
EA006606B1
(ru)
|
2000-02-24 |
2006-02-24 |
Вашингтон Юниверсити |
Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
|
|
JP2004500099A
(ja)
|
2000-03-08 |
2004-01-08 |
ナショナル ジューイッシュ メディカル アンド リサーチ センター |
ホスファチジルセリンレセプターおよびその使用
|
|
AU2001245647A1
(en)
|
2000-03-14 |
2001-09-24 |
Idec Pharmaceuticals Corporation |
Antibodies that bind phosphatidyl serine and a method of their use
|
|
US20030072743A1
(en)
|
2000-05-05 |
2003-04-17 |
Matthew Albert |
Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
JP4572276B2
(ja)
|
2001-06-29 |
2010-11-04 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
Ｔ細胞調節遺伝子およびその使用方法
|
|
US8709412B2
(en)
*
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
WO2004004667A2
(en)
|
2002-03-15 |
2004-01-15 |
The Regents Of The University Of California |
Method of immunotherapy
|
|
US7247303B2
(en)
|
2002-07-15 |
2007-07-24 |
Board Of Regents, The University Of Texas System |
Selected antibody CDRs for binding to aminophospholipids
|
|
AU2003209753A1
(en)
|
2003-01-27 |
2004-08-23 |
Crucell Holland B.V. |
Internalising human binding molecules against cd72
|
|
US8198020B2
(en)
|
2003-08-22 |
2012-06-12 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
WO2005047860A2
(en)
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
|
TW200539890A
(en)
|
2004-03-12 |
2005-12-16 |
Brigham & Womens Hospital |
Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
|
|
BRPI0509139A
(pt)
|
2004-03-24 |
2007-08-28 |
Telos Fharmaceuticals Inc |
composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
|
|
GB0414055D0
(en)
|
2004-06-23 |
2004-07-28 |
Univ Edinburgh |
Specific binding members and uses thereof
|
|
CA2591914C
(en)
|
2005-01-24 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
|
|
US20060257359A1
(en)
|
2005-02-28 |
2006-11-16 |
Cedric Francois |
Modifying macrophage phenotype for treatment of disease
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
MY169492A
(en)
|
2006-03-23 |
2019-04-15 |
Bioarctic Neuroscience Ab |
Improved protofibril selective antibodies and the use thereof
|
|
RU2498999C2
(ru)
|
2006-07-14 |
2013-11-20 |
Ац Иммуне Са |
Гуманизированное антитело к амилоиду бета
|
|
WO2008042814A2
(en)
|
2006-09-29 |
2008-04-10 |
California Institute Of Technology |
Mart-1 t cell receptors
|
|
BRPI0816769A2
(pt)
|
2007-09-12 |
2016-11-29 |
Hoffmann La Roche |
combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
|
|
WO2009055730A1
(en)
|
2007-10-25 |
2009-04-30 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
HRP20150831T1
(hr)
|
2008-12-19 |
2015-10-09 |
Biogen International Neuroscience Gmbh |
Humana anti-alfa- sinuklein auto-protutijela
|
|
EP2427212B1
(en)
|
2009-05-08 |
2017-08-23 |
Vaccinex, Inc. |
Anti-cd100 antibodies and methods for using the same
|
|
WO2011085070A2
(en)
|
2010-01-06 |
2011-07-14 |
Virginia Tech Intellectual Properties, Inc. |
Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
US20140162290A1
(en)
|
2012-11-22 |
2014-06-12 |
Riken |
Probe for detecting dead cell
|
|
US20160145348A1
(en)
|
2013-03-14 |
2016-05-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
WO2015066262A1
(en)
|
2013-11-04 |
2015-05-07 |
Trustees Of Dartmouth College |
Methods for preventing toxicity of adoptive cell therapy
|
|
DK3105335T3
(da)
|
2014-02-14 |
2020-01-13 |
Univ Texas |
Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
|
|
PT3149031T
(pt)
|
2014-05-29 |
2020-03-25 |
Us Health |
Receptores de células t anti-e7 do papilomavírus humano 16
|
|
TWI734975B
(zh)
|
2014-06-27 |
2021-08-01 |
美商Ｃ２Ｎ醫療診斷有限責任公司 |
人類化抗-tau抗體
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
WO2016176639A1
(en)
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2017011316A1
(en)
|
2015-07-10 |
2017-01-19 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
|
|
JP7032304B2
(ja)
|
2015-07-28 |
2022-03-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用
|
|
CN107207613B
(zh)
|
2015-08-07 |
2020-06-09 |
深圳市体内生物医药科技有限公司 |
含Toll样受体胞内结构域的嵌合抗原受体
|
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
|
CN106467573B
(zh)
|
2015-08-21 |
2021-05-25 |
佧珐药业有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
EP3334764A2
(en)
|
2015-10-13 |
2018-06-20 |
Brigham Young University |
Macrophage chimeric antigen receptor (moto-car) in imunotherapy
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
WO2017083700A1
(en)
|
2015-11-13 |
2017-05-18 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
|
|
US20180186855A1
(en)
|
2016-03-23 |
2018-07-05 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
WO2017205747A1
(en)
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
|
CN107522786A
(zh)
|
2016-06-20 |
2017-12-29 |
深圳市体内生物医药科技有限公司 |
一种分子、表达其的细胞及其制备方法和用途
|
|
WO2018031419A1
(en)
*
|
2016-08-12 |
2018-02-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
|
|
WO2018064076A1
(en)
|
2016-09-27 |
2018-04-05 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
US11541076B2
(en)
|
2017-01-13 |
2023-01-03 |
Celdara Medical, Llc |
Chimeric antigen receptors targeting TIM-1
|
|
EP3624834A1
(en)
|
2017-05-17 |
2020-03-25 |
Thunder Biotech Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
WO2018220224A1
(en)
|
2017-06-02 |
2018-12-06 |
Medirista Biotechnologies Ab |
Lipid-related antigens and antibodies directed against them
|
|
DK3688032T3
(da)
|
2017-09-26 |
2025-12-15 |
Cero Therapeutics Holdings Inc |
Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder
|
|
WO2019079529A1
(en)
|
2017-10-17 |
2019-04-25 |
The Translational Genomics Research Institute |
TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
|
|
GB201717974D0
(en)
|
2017-10-31 |
2017-12-13 |
Univ Court Of The Univ Of Aberdeen |
Modified receptors
|
|
US11866731B2
(en)
|
2017-11-10 |
2024-01-09 |
Chineo Medical Technology Co., Ltd |
Modified immune cells and uses thereof
|
|
US12344662B2
(en)
|
2018-02-09 |
2025-07-01 |
The Trustees Of Dartmouth College |
Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders
|
|
US12291557B2
(en)
|
2018-03-28 |
2025-05-06 |
Cero Therapeutics Holdings, Inc. |
Chimeric TIM4 receptors and uses thereof
|
|
MX2020010235A
(es)
|
2018-03-28 |
2020-10-28 |
Cero Therapeutics Inc |
Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
|
|
WO2019191332A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
|
RU2020135107A
(ru)
|
2018-03-28 |
2022-04-29 |
Серо Терапьютикс, Инк. |
Клеточные иммунотерапевтические композиции и их применения
|
|
CN112368298A
(zh)
|
2018-06-22 |
2021-02-12 |
凯德药业股份有限公司 |
嵌合跨膜蛋白及其用途
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
EP3892333A4
(en)
|
2018-12-07 |
2022-11-30 |
CRAGE medical Co., Limited |
ANTI-TUMOR POLYIMMUNOTHERAPY
|
|
AU2020266595A1
(en)
|
2019-04-30 |
2021-11-25 |
Create Medicines, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
EP3994175A4
(en)
|
2019-07-03 |
2023-03-15 |
The Regents of the University of California |
IMMUNOTHERAPY TARGETING THE CD72 CELL SURFACE MARKER FOR THE TREATMENT OF B-CELL MALIGNITIES
|
|
US20240058446A1
(en)
|
2019-10-03 |
2024-02-22 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
US20210253696A1
(en)
|
2020-01-21 |
2021-08-19 |
Cero Therapeutics, Inc. |
Bivalent chimeric engulfment receptors and uses thereof
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
JP7868033B2
(ja)
|
2020-08-14 |
2026-06-01 |
セロ・セラピューティクス・ホールディングス・インコーポレイテッド |
キメラｔｉｍ受容体およびその使用
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
FI4376874T3
(fi)
|
2021-07-28 |
2026-04-08 |
Cero Therapeutics Holdings Inc |
Kimeerisiä tim4-reseptoreita ja niiden käyttöjä
|